A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
06/04/2022at 15:10

FDA grants Sanofi's blockbuster priority review in a new indication

Sanofi’s drug Dupixent has now received the US health authority’s Breakthrough Therapy, Orphan Drug and Priority Review designations, the latter of which in a new indication for people with inflamed esophagi due to allergies.
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

French Sanofi has been granted Priority Review by the US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the indication for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Violeta Santos Moura/Reuters/Ritzau Scanpix

    Sanofi lifts sales potential of blockbuster drug to USD 14.5bn

    For subscribers

  • Photo: VIOLETA SANTOS MOURA/REUTERS / X07448

    Sanofi sees higher earnings as blockbuster skin drug soars

    For subscribers

  • Photo: Charles Platiau/Reuters/Ritzau Scanpix

    Sanofi upgrades 2021 guidance once again – Dupixent drives growth

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Sydbank/pr
Pharma & biotech

Analyst: Priority review for Lundbeck-Otsuka Alzheimer's agitation drug signals unmet need

A four-month reduction to case processing is positive and could boost Lundbeck stock, says an analyst, noting that the regulatory win is also recognition of an unmet medical need.

For subscribers

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Foto: Lundbeck / Pr
Pharma & biotech

Lundbeck and Otsuka win FDA priority review of Alzheimer's agitation drug

The two pharmaceutical firms have taken a step toward entering the market with Alzheimer’s agitation drug brexpiprazol.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Head of International Sales

  • Lead Data Architect

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Jobs

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Head of International Sales

  • Lead Data Architect

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge